2024年4月26日
This protocol allows for the in vivo quantification of venous compliance and distensibility using catheterization and 3D angiography as a survival procedure allowing for a variety of potential applications.
We aim to improve long-term outcomes for congenital-heart-disease patients using a regenerative medicine approach. Our tissue-engineered vascular graft develops into a neo vessel comprised of the patient's own cells. Our goal is to make comparisons between our graft, the native vein, and the clinical standard polytetrafluoroethylene or PTFE.
We have established that our neo vessel displays growth capacity and that it approaches native vessel functionality. Using this method, we've also recently demonstrated that the neo vessel retains compliance and distensibility at a long-term time point, and is resistant to the formation of dystrophic calcification. Using 3D angiography allows us to image the entire path of the thoracic inferior vena cava in our ovine large-animal model.
In addition to allowing us to view the morphology of the vessel, it also allows for post-capture orientation adjustments to ensure we're obtaining measurements from a true cross-section. Our in-vivo method allows us to determine the capacity for vessel compliance and distensibility in its native context. Additionally, it allows us to take longitudinal measurements of the same study animal, which is necessary to track changes in neo-vessel development and remodeling.
本方案通过导管插入术和三维血管造影技术,实现了对静脉顺应性和扩张性的体内定量评估。该可存活操作在改善先天性心脏病患者预后方面具有多种潜在应用价值。
对静脉顺应性和扩张性的体内定量评估填补了血管移植物研发中的关键空白,能够在生理条件下将工程化构建物与天然血管进行直接比较。该技术可提高对移植物性能的预测可靠性,支持再生医学与心血管器械研发管线交叉领域中的风险调整决策。在大型动物模型中进行纵向测量,使该方法成为实现转化连续性和项目筛选的战略性工具。
该方法可融入血管移植物从发现到临床前研究的连续过程中,架起早期机制研究与大动物模型转化验证之间的桥梁。